- Home
- DSGN vs MVT Comparison
DSGN vs MVT Comparison
Compare DSGN & MVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- MVT
- Stock Information
- Founded
- DSGN 2017
- MVT 1993
- Country
- DSGN United States
- MVT United States
- Employees
- DSGN N/A
- MVT N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- MVT Investment Bankers/Brokers/Service
- Sector
- DSGN Health Care
- MVT Finance
- Exchange
- DSGN Nasdaq
- MVT Nasdaq
- Market Cap
- DSGN 224.8M
- MVT 214.7M
- IPO Year
- DSGN 2021
- MVT N/A
- Fundamental
- Price
- DSGN $3.71
- MVT $10.10
- Analyst Decision
- DSGN Hold
- MVT
- Analyst Count
- DSGN 1
- MVT 0
- Target Price
- DSGN $4.00
- MVT N/A
- AVG Volume (30 Days)
- DSGN 93.8K
- MVT 49.7K
- Earning Date
- DSGN 08-04-2025
- MVT 01-01-0001
- Dividend Yield
- DSGN N/A
- MVT 4.15%
- EPS Growth
- DSGN N/A
- MVT N/A
- EPS
- DSGN N/A
- MVT N/A
- Revenue
- DSGN N/A
- MVT N/A
- Revenue This Year
- DSGN N/A
- MVT N/A
- Revenue Next Year
- DSGN N/A
- MVT N/A
- P/E Ratio
- DSGN N/A
- MVT N/A
- Revenue Growth
- DSGN N/A
- MVT N/A
- 52 Week Low
- DSGN $2.60
- MVT $8.96
- 52 Week High
- DSGN $7.77
- MVT $11.17
- Technical
- Relative Strength Index (RSI)
- DSGN 47.78
- MVT 46.02
- Support Level
- DSGN $3.66
- MVT $10.12
- Resistance Level
- DSGN $3.84
- MVT $10.26
- Average True Range (ATR)
- DSGN 0.25
- MVT 0.08
- MACD
- DSGN -0.02
- MVT 0.01
- Stochastic Oscillator
- DSGN 18.06
- MVT 33.33
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About MVT Blackrock MuniVest Fund II Inc.
Blackrock Munivest Fund II Inc is a closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Health, Utilities, Education, Housing, and other sectors.